These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30660499)

  • 1. Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study.
    Tarazi H; El-Gamal MI; Oh CH
    Bioorg Med Chem; 2019 Feb; 27(4):655-663. PubMed ID: 30660499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
    Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
    Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
    Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
    Anbar HS; El-Gamal MI; Tarazi H; Lee BS; Jeon HR; Kwon D; Oh CH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1712-1726. PubMed ID: 32962435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
    Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
    Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, in vitro antiproliferative activity, and kinase inhibitory effects of pyrazole-containing diarylureas and diarylamides.
    El-Gamal MI; Park BJ; Oh CH
    Eur J Med Chem; 2018 Aug; 156():230-239. PubMed ID: 30006168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
    Yang Y; Qin J; Liu H; Yao X
    J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Biological Evaluation of Novel Type II B-Raf
    Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
    ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
    Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis,
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1534-1543. PubMed ID: 31452407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
    Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
    Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF
    Wang CR; Wang ZF; Shi L; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2382-2390. PubMed ID: 29934244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
    Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors.
    Yang YS; Yang B; Zou Y; Li G; Zhu HL
    Bioorg Med Chem; 2016 Jul; 24(13):3052-3061. PubMed ID: 27238841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.